Kiniksa Pharmaceuticals International, plc (KNSA) EBITDA
Kiniksa Pharmaceuticals International, plc (KNSA) EBITDA
- 2026-03-31: Basis Reported; EBITDA (m); Operating income $29.27M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $24.02M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income $20.16M; Depreciation and amortization (m).
- 2025-03-31: Basis Reported; EBITDA (m); Operating income $13.27M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-03-31 | Reported | (m) | $29.27M | (m) | $214.27M | (m) | $161.00K | $50.20M | $20.80M | $27.48M | $61.15M | $10.09M |
|---|
| 2025-09-30 | Reported | (m) | $24.02M | (m) | $180.85M | (m) | $671.00K* | $33.68M* | $20.26M | $24.17M | $49.10M | $8.72M |
|---|
| 2025-06-30 | Reported | (m) | $20.16M | (m) | $156.80M | (m) | $165.00K* | $28.09M* | $18.60M | $18.75M | $46.86M | $5.04M |
|---|
| 2025-03-31 | Reported | (m) | $13.27M | (m) | $137.78M | (m) | $99.00K | $22.32M | $17.87M | $19.32M | $43.53M | $7.03M |
|---|
| 2024-09-30 | Reported | (m) | -$9.66M | (m) | $112.21M | (m) | $0.00* | -$2.24M* | $20.11M | $26.06M | $46.40M | $5.49M |
|---|
| 2024-06-30 | Reported | (m) | -$117.00K | (m) | $108.63M | (m) | $0.00* | $5.17M* | $12.32M | $24.02M | $42.40M | $6.21M |
|---|
| 2024-03-31 | Reported | (m) | -$16.54M | (m) | $79.86M | (m) | $84.00K | $3.99M | $10.58M | $26.33M | $38.68M | $3.43M |
|---|
| 2023-09-30 | Reported | (m) | -$10.93M | (m) | $67.05M | (m) | $16.00K* | $16.99M* | $9.09M | $17.11M | $34.47M | $5.36M |
|---|
| 2023-06-30 | Reported | (m) | -$3.15M | (m) | $71.47M | (m) | $34.00K* | -$3.74M* | $7.70M | $23.77M | $29.18M | -$16.21M |
|---|
| 2023-03-31 | Reported | (m) | -$11.20M | (m) | $48.34M | (m) | $24.00K | -$4.27M | $7.04M | $15.17M | $29.05M | $2.91M |
|---|
| 2022-09-30 | Reported | (m) | $46.41M | (m) | $99.14M | (m) | $22.00K* | $62.05M* | $6.94M | $16.48M | $24.68M | -$177.36M |
|---|
| 2022-06-30 | Reported | (m) | -$19.37M | (m) | $26.97M | (m) | (m) | -$7.82M* | $5.03M | $13.80M | $23.84M | $716.00K |
|---|
| 2022-03-31 | Reported | (m) | -$23.32M | (m) | $32.19M | (m) | (m) | -$36.85M | (m) | $20.82M | $22.22M | $1.93M |
|---|
| 2021-09-30 | Reported | (m) | -$30.67M | (m) | $12.10M | (m) | $51.00K* | -$28.51M* | $2.77M | $19.24M | $20.76M | -$118.00K |
|---|
| 2021-06-30 | Reported | (m) | -$40.55M | (m) | $7.70M | (m) | $59.00K* | -$38.78M* | $2.47M | $23.95M | $21.85M | $1.01M |
|---|
| 2021-03-31 | Reported | (m) | -$49.28M | (m) | (m) | (m) | $54.00K | -$40.12M | (m) | $28.68M | $20.60M | $210.00K |
|---|
| 2020-09-30 | Reported | (m) | -$43.22M | (m) | (m) | (m) | $5.00K* | -$34.32M* | (m) | $31.42M | $11.80M | $667.00K |
|---|
| 2020-06-30 | Reported | (m) | -$31.86M | (m) | (m) | (m) | $0.00* | -$29.22M* | (m) | $22.32M | $9.54M | $5.88M |
|---|
| 2020-03-31 | Reported | (m) | -$29.39M | (m) | (m) | (m) | $223.00K | -$31.80M | (m) | $20.90M | (m) | -$2.18M |
|---|
| 2019-09-30 | Reported | (m) | -$30.45M | (m) | (m) | (m) | $440.00K* | -$29.27M* | (m) | $22.01M | (m) | -$2.00M |
|---|
| 2019-06-30 | Reported | (m) | -$39.29M | (m) | (m) | (m) | -$794.00K* | -$41.68M* | (m) | $30.85M | (m) | -$374.00K |
|---|
| 2019-03-31 | Reported | (m) | -$67.65M | (m) | (m) | (m) | $1.56M | -$63.26M | (m) | $59.25M | (m) | -$17.00K |
|---|
| 2018-09-30 | Reported | (m) | -$26.16M | (m) | (m) | (m) | $963.00K* | -$20.48M* | (m) | $20.64M | (m) | -$131.00K |
|---|
| 2018-06-30 | Reported | (m) | -$21.53M | (m) | (m) | (m) | $236.00K* | -$17.92M* | (m) | $17.20M | (m) | -$202.00K |
|---|
| 2018-03-31 | Reported | (m) | -$16.34M | (m) | (m) | (m) | $75.00K | -$14.97M | (m) | $12.63M | (m) | -$53.00K |
|---|
| 2017-09-30 | Reported | (m) | -$16.25M | (m) | (m) | (m) | $28.00K* | -$10.94M* | (m) | $14.01M | (m) | -$51.00K |
|---|
| 2017-06-30 | Reported | (m) | -$11.39M | (m) | (m) | (m) | (m) | (m) | (m) | $9.27M | (m) | -$36.00K |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | (m) | $77.22M | (m) | $677.56M | (m) | $1.57M | $137.99M | $77.67M | $96.85M | $196.27M | $29.86M |
|---|
| 2024-12-31 | Reported | (m) | -$45.62M | (m) | $423.24M | (m) | $277.00K | $25.69M | $60.91M | $111.62M | $168.01M | $7.04M |
|---|
| 2023-12-31 | Reported | (m) | -$25.20M | (m) | $270.26M | (m) | $130.00K | $13.30M | $33.41M | $76.10M | $129.43M | -$30.74M |
|---|
| 2022-12-31 | Reported | (m) | $9.77M | (m) | $220.18M | (m) | $105.00K | $5.81M | $22.89M | $65.49M | $97.95M | -$172.34M |
|---|
| 2021-12-31 | Reported | (m) | -$156.64M | (m) | $38.54M | (m) | $415.00K | -$126.30M | $9.10M | $99.30M | $85.95M | $1.39M |
|---|
| 2020-12-31 | Reported | (m) | -$157.36M | (m) | (m) | (m) | $283.00K | -$136.53M | (m) | $112.04M | $45.32M | $5.15M |
|---|
| 2019-12-31 | Reported | (m) | -$169.96M | (m) | (m) | (m) | $3.20M | -$158.37M | (m) | $135.00M | $34.96M | -$2.05M |
|---|
| 2018-12-31 | Reported | (m) | -$108.16M | (m) | (m) | (m) | $5.29M | -$81.01M | (m) | $86.60M | (m) | -$214.00K |
|---|
| 2017-12-31 | Reported | (m) | -$65.40M | (m) | (m) | (m) | $69.00K | -$50.22M | (m) | $56.36M | (m) | $2.00K |
|---|